Zelsuvmi™

Drug - Zelsuvmi™ (berdazimer) [LNHC, Inc.]

May 2026

Therapeutic area - Keratolytics

Approval criteria

• The patient has a diagnosis of molluscum contagiosum (MC) AND
• The patient’s age is within FDA labeling for the requested indication for the requested agent AND
• The patient will NOT be using the requested agent in combination with another conventional therapy (e.g., cantharidin, cryotherapy, curettage, podofilox) for the requested indication AND
• The patient does NOT have any FDA labeled contraindications to the requested agent AND
• The patient has ONE of the following:
  • Tried and had an inadequate response to ONE conventional therapy (e.g.,cantharidin, cryotherapy, curettage, podofilox) OR
  • An intolerance or hypersensitivity to ONE conventional therapy OR
  • An FDA labeled contraindication to ALL conventional therapy AND

Quantity limits

• 1 carton per 4 weeks for 12 weeks

Questions?

Provider Call Center: (844) 575-7887